Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » PCR » OpGen Progresses on Pipeline of Highly Multiplexed Drug-Resistant Bacteria Tests

OpGen Progresses on Pipeline of Highly Multiplexed Drug-Resistant Bacteria Tests

Aug 20, 2019
|
Madeleine Johnson
Premium

NEW YORK – OpGen is forging its core technologies into highly multiplexed molecular diagnostic assays to detect pathogens and resistance genes. While companies in the rapid antimicrobial resistance (AMR) space in general have struggled to achieve a good valuation of their technologies and remain financially solvent, OpGen's collaborations have recently made a difference to its bottom line.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

A Start

The Los Angeles Times reports that experts say Moderna's investigational COVID-19 vaccine results seem to be a step in the right direction, but that more testing is needed.

Just Go 'Round the CDC

The Washington Post reports a new coronavirus data reporting protocol goes around the Centers for Disease Control and Prevention.

Student Visa Directive Rescinded

The Trump Administration has reversed its policy that could have stripped international students of their visas, the New York Times says.

Cell Studies on Blood Features of Severe COVID-19 Cases, Infection-Related Phosphorylation Shifts, More

In Cell this week: proteomic and metabolomic analysis of blood from COVID-19 patients, change in phosphorylation with infection, and more.

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

Sponsored by
Roche

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Aug
19
Featured Webinar

Case Study: An IVD Manufacturer’s Experience Building a Complete Sample-to-Result Workflow

Sponsored by
UgenTec

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Sponsored by
Roche

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

What's Popular?

In PCR

  1. BioMérieux BioFire Respiratory Panel With SARS-CoV-2 Target Nabs CE Mark

  2. Helix, San Diego County Partner on COVID-19 Molecular Testing

  3. SARS-CoV-2 Pandemic May Promote Progress in Paper MDx

  4. Paragon Genomics Betting Updated SARS-CoV-2 NGS Kit Will Enable High-Throughput Research, Testing

    Premium

  5. FDA Grants EUA to KogeneBiotech, Trax Management, and Compass Laboratory Coronavirus Tests

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.